Partner Nate Lacktman was quoted in a Bloomberg BNA article, “Telemedicine Providers Anticipating Changes to Remote Prescribing Rules,” covering the expansion of allowed remote prescriptions of controlled substances.
“We expect the Drug Enforcement Administration (DEA) to release that rule sooner rather than later,” Lacktman said.
He also explained that although there are an increasing amount of states changing their laws to align with remote prescriptions, “some states, in an attempt to reconcile the provisions of the Ryan Haight Act with their own laws, are building the terms of the federal statute directly into their state regulations.” He warned against this practice because it ultimately might not benefit the patients.
“We expect the Drug Enforcement Administration (DEA) to release that rule sooner rather than later,” Lacktman said.
He also explained that although there are an increasing amount of states changing their laws to align with remote prescriptions, “some states, in an attempt to reconcile the provisions of the Ryan Haight Act with their own laws, are building the terms of the federal statute directly into their state regulations.” He warned against this practice because it ultimately might not benefit the patients.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”